- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00992745
A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Laguna Niguel, California, United States, 92677
- West Coast Radiology Centers
-
Newport Beach, California, United States, 92663
- Pacific Coast Imaging
-
San Francisco, California, United States, 94143
- University of California - San Francisco
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland
-
-
New York
-
New York, New York, United States, 10065
- New York Presbyterian Hospital - Weill Cornell Medical College
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- Vanguard Urologic Research Foundation
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Subjects must meet all of the following criteria to be enrolled in this study.
- Male aged 18 years or older
- Signed written informed consent and willingness to comply with protocol requirements
- Histologic diagnosis of prostate cancer by validated history and/or biopsy of the prostate or of a metastatic lesion.
Evidence of metastatic disease as documented by an abnormal bone scan and CT scan or MRI plus:
Castration/anti androgen therapy naïve/sensitive:
- Gleason Score ≥ 7 and PSA ≥ 2.0 ng/mL with history of prostatectomy or primary radiation therapy of the prostate gland and prior undetectable PSA or; PSA > 10.0 ng/mL if intact prostate, or
- Gleason score ≤ 6 and PSA is ≥ 20 ng/mL, or
- Gleason Score ≥ 8 and any doubling of PSA, or PSA > 0.5 ng/mL, or
- Clinical Stage 3 and Gleason Score ≥ 8
If on anti androgen therapy, must have initiated therapy at least 4 weeks prior to treatment.
Castration/anti androgen therapy resistant:
- Patients must have current or historical evidence of disease progression concomitant with surgical (orchiectomy) or medical castration (LHRH analogue); anti androgen withdrawal (4 weeks for flutamide and 6 weeks for nilutamide or bicalutamide) is necessary only for patients on anti androgens who have demonstrated a > 3 month duration of beneficial response to anti androgens; progression is demonstrated by any of the following:
I. PSA progression: 2 serial rising PSA determinations at least 14 days apart over the PSA nadir, with the last measurement ≥ 2 ng/mL
II. Progression of measurable disease, or progression of non measurable disease as defined by:
i. Soft tissue disease: The appearance of one or more new lesions, and/or unequivocal worsening of non measurable disease when compared to imaging studies acquired during castration therapy or against the precastration studies if there was no response, or ii. Bone disease: Appearance of two or more new areas of abnormal uptake on bone scan when compared to imaging studies acquired during castration therapy or against the pre castration studies if there was no response.
III. Increased uptake of pre existing lesions on bone scan does not constitute progression.
IV. Testosterone ≤ 50 ng/dL achieved via medical or surgical castration.
- Male subjects who are fertile agree to use an acceptable form of birth control, defined as abstinence, barrier or other acceptable, effective contraceptive method throughout the study period. A second form of barrier birth control must be utilized if a subject's partner is using oral contraception until at least seven days after the last injection.
- Karnofsky performance is ≥ 50
Adequate hematologic, renal and liver function:
- WBC ≥ 2.0×103/mm3 (ANC > 1.0 x 103 mm3)
- Platelet count ≥ 75×103/mm3
- Hemoglobin ≥ 9.0 g/dL
- Creatinine ≤ 2.5 mg/dL
- Total bilirubin ≤ 2x ULN
- AST, ALT ≤ 5x ULN
Exclusion Criteria:
- Karnofsky performance status of < 50
- Subject has received a permanent prostate brachytherapy implant within the last 3 months for 103Pd implants or 12 months for 125I implants
- Subject was administered a diagnostic radioisotope within 5 physical half lives of that radioisotope prior to study enrollment
- Subject has received an investigational compound and/or medical device or has been part of an investigational study within the past 30 days before enrollment into this study
- Any treatment with radiopharmaceuticals, e.g. Strontium 89 and Samarium 153 within 6 months prior to enrollment
- Ketoconazole or anti androgens (flutamide, nilutamide, bicalutamide) within 4 weeks prior to enrollment. Patients who demonstrate an antiandrogen withdrawal response, defined as a > 25% drop in PSA within 4 weeks (flutamide) or 6 weeks (nilutamide, bicalutamide) of stopping a non steroidal anti androgen, are not eligible until the PSA rises above the nadir observed after anti androgen withdrawal
- Initiation of bisphosphonate therapy within 28 days prior to enrollment. Patients taking bisphosphonates should not have their dosing regimen altered unless medically warranted in the interval between baseline scans and end of study
- Subject has any medical condition or other circumstances which, in the opinion of the Investigator, would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post dose follow up examinations
- Subject is determined by the Investigator to be clinically unsuitable for the study
- If the subject has had any other malignancies within the past year, other than basal or squamous cell carcinoma of the skin, diagnosis and location must be defined or be defined as clinically controlled or treated to complete response
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Previous ProstaScint®
Subjects with a previous 111-In capromab pendetide image of sufficient quality obtained within 60 days of study enrollment will receive 123-I-MIP-1072 alone.
|
Single 10 mCi intravenous injection
Other Names:
Single 5 mCi intravenous injection
Other Names:
|
Experimental: No Previous ProstaScint®
Subjects without a previous 111-In capromab pendetide image of sufficient quality obtained within 60 days of study enrollment will receive 123-I-MIP-1072 and 111-In capromab pendetide imaging.
|
Single 10 mCi intravenous injection
Other Names:
Single 5 mCi intravenous injection
Other Names:
Single 5 mCi intravenous injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Estimate the imaging sensitivity and specificity of 10.0 mCi or 5.0 mCi of 123I MIP 1072 compared to 5 mCi of 111In capromab pendetide in subjects with metastatic prostate cancer by determining the presence and extent of the disease.
Time Frame: 24 hours post-injection
|
24 hours post-injection
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Examine the imaging sensitivity and specificity of 10.0 mCi or 5.0 mCi of 123I MIP 1072 compared to 5 mCi of 111In capromab pendetide on a per lesion basis in subjects with metastatic prostate cancer
Time Frame: Through 2 weeks post-injection
|
Through 2 weeks post-injection
|
To describe the safety of administering 10.0 mCi and 5.0 mCi of 123I MIP 1072 for the detection of metastatic prostate cancer
Time Frame: Through 2 weeks post-injection
|
Through 2 weeks post-injection
|
Collaborators and Investigators
Investigators
- Principal Investigator: Mack Roach, MD, University of California, San Francisco
- Principal Investigator: Jeffrey Dobkin, MD, Pacific Coast Imaging
- Principal Investigator: Stanley Goldsmith, MD, NY Presbyterian Hospital - Weill Cornell Medical Center
- Principal Investigator: Edward Coleman, MD, Duke University
- Principal Investigator: Arif Hussain, MD, University of Maryland
- Principal Investigator: Kevin Slawin, MD, Vanguard Urologic Research Foundation
- Principal Investigator: Samuel L Kipper, MD, West Coast Radiology Centerse
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TX-P103
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingProstate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
Clinical Trials on 123-I-MIP-1072
-
Molecular Insight Pharmaceuticals, Inc.Completed
-
Molecular Insight Pharmaceuticals, Inc.National Cancer Institute (NCI)Withdrawn
-
Institute for Neurodegenerative DisordersTerminatedAlzheimer's DiseaseUnited States
-
Molecular Insight Pharmaceuticals, Inc.TerminatedMetastatic MelanomaUnited States
-
Molecular Insight Pharmaceuticals, Inc.CompletedAcute Coronary SyndromeUnited States, Canada
-
Alseres Pharmaceuticals, IncUnknownParkinsonian SyndromesUnited States
-
GE HealthcareCompletedCongestive Heart FailureUnited States
-
Institute for Neurodegenerative DisordersTerminatedAlzheimer's DiseaseUnited States
-
GE Healthcarei3 StatprobeCompletedParkinsonian SyndromesUnited States, France
-
Ake NorbergCompleted